

Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready to Start	Date of First Patient Recruited	Non-Confirmation Status	Duration between Date site selected and First Patient (days)	A - Permissions delayed/denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments	Reasons for delay correspond to:	
19/NE/0215	234453	Myeloma XIV (FITNEss). Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma: A phase III trial to compare standard and frailty-adjusted induction therapy with ixazomib, lenalidomide and dexamethasone (IRD) and maintenance lenalidomide (R) to lenalidomide plus ixazomib (R+I).	28/06/2019	02/12/2019	07/11/2019	22/01/2020	19/02/2020	06/08/2020	29/09/2020		302				Y								The Sponsor were not ready to open sites; they hoped to open sites in February 2020. Sponsor due to open sites in February 2020, however this got delayed further and in March 2020 the Sponsor put this study on hold due to the global pandemic. First patient recruited after restart at site	Sponsor
20/EE/0101	281712	Randomised Evaluation of COVID-19 Therapy (RECOVERY)	17/03/2020	17/03/2020	17/03/2020	13/03/2020	25/03/2020	25/03/2020	01/04/2020		15													
20/WS/0070	275797	FINEARTS-HF (Finerenone trial in patients with Heart Failure)	06/11/2019	11/08/2020	04/06/2020	06/10/2020	06/10/2020	08/10/2020							Y								Site staff prioritised UPH Covid-19 studies	NHS Provider
19/NW/0712	272690	PACIFIC-AF Multicenter, randomized, active comparator-controlled, double-blind, double-dummy, parallel group, dose-finding Phase 2 study to compare the safety of the oral FXIa inhibitor BAY 2433334 to apixaban in patients with atrial fibrillation	18/09/2019	02/09/2020	31/01/2020										Y								Site staff prioritised UPH Covid-19 studies	NHS Provider